Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 11/2008

01.11.2008 | Original Paper

Increased soluble CD44 concentrations are associated with larger tumor size and lymph node metastasis in breast cancer patients

verfasst von: Sebastian Mayer, Axel zur Hausen, Dirk Otto Watermann, Stefan Stamm, Markus Jäger, Gerald Gitsch, Elmar Stickeler

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 11/2008

Einloggen, um Zugang zu erhalten

Abstract

Purpose

CD44 is a cell surface glycoprotein involved in cell–cell and cell–substrate interactions, which may be shed or released into circulation by proteolytic enzymatic mechanisms. Alternative splicing of CD44 and aberrant levels of soluble CD44 variants in the serum of cancer patients have been correlated to tumor progression and metastasis in different tumors including breast cancer. In this study we evaluated the clinical value of CD44 serum levels (sCD44) in patients with primary breast cancer.

Methods

Concentrations of soluble isoforms sCD44std, sCD44v5 and sCD44v6 were determined with a sensitive ELISA and normalized against the total protein concentration (TP). Pre-operative serum samples from 82 patients and 67 age-matched healthy blood donors were analyzed. The results were correlated to clinico-pathological parameters (tumor size, grading, lymph node metastasis, etc.).

Results

In sera of breast cancer patients, we detected elevated concentrations of sCD44v6 (P = 0.0001) and total protein TP (P = 0.0001) in comparison to healthy controls, whereas overall sCD44 (sCD44std) and sCD44v5 did not differ. Patients with sCD44v6-concentrations above the 75%-percentile showed an increased T stage (2.9 cm vs. 1.8 cm) as well as a higher risk for lymph node metastasis (55% vs. 35%). In breast cancer patients with lymph node metastasis the median value of sCD44v6 was significantly higher (P = 0.025) in comparison to patients without lymph node metastasis and healthy controls.

Conclusions

Our data suggest an upregulated expression of alternatively spliced soluble CD44 isoforms in breast cancer patients. The specific alterations of certain CD44 isoform concentrations (especially sCD44v6) may reflect disturbances of the nuclear splicing machinery in tumor cells. The clinical significance of our findings are underlined by the positive correlation of elevated sCD44v6 concentrations and lymph node metastases (r s = 0.25).
Literatur
Zurück zum Zitat Fichter M et al (1997) Expression of CD44 isoforms in neuroblastoma cells is regulated by PI 3-kinase and protein kinase C. Oncogene 14(23):2817–2824PubMedCrossRef Fichter M et al (1997) Expression of CD44 isoforms in neuroblastoma cells is regulated by PI 3-kinase and protein kinase C. Oncogene 14(23):2817–2824PubMedCrossRef
Zurück zum Zitat Friedrichs K et al (1995) CD44 isoforms correlate with cellular differentiation but not with prognosis in human breast cancer. Cancer Res 55(22):5424–5433PubMed Friedrichs K et al (1995) CD44 isoforms correlate with cellular differentiation but not with prognosis in human breast cancer. Cancer Res 55(22):5424–5433PubMed
Zurück zum Zitat Guriec N et al (1996) CD44 exon 6 expression as a possible early prognostic factor in primary node negative breast carcinoma. Clin Exp Metastasis 14(5):434–439PubMedCrossRef Guriec N et al (1996) CD44 exon 6 expression as a possible early prognostic factor in primary node negative breast carcinoma. Clin Exp Metastasis 14(5):434–439PubMedCrossRef
Zurück zum Zitat Guriec N et al (1997) CD44 isoforms with exon v6 and metastasis of primary N0M0 breast carcinomas. Breast Cancer Res Treat 44(3):261–268PubMedCrossRef Guriec N et al (1997) CD44 isoforms with exon v6 and metastasis of primary N0M0 breast carcinomas. Breast Cancer Res Treat 44(3):261–268PubMedCrossRef
Zurück zum Zitat Kaufmann M et al (1995) CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet 345(8950):615–619PubMedCrossRef Kaufmann M et al (1995) CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet 345(8950):615–619PubMedCrossRef
Zurück zum Zitat Kawano T et al (2005a) Evaluation of soluble adhesion molecules CD44 (CD44st, CD44v5, CD44v6), ICAM-1, and VCAM-1 as tumor markers in head and neck cancer. Am J Otolaryngol 26(5):308–313PubMedCrossRef Kawano T et al (2005a) Evaluation of soluble adhesion molecules CD44 (CD44st, CD44v5, CD44v6), ICAM-1, and VCAM-1 as tumor markers in head and neck cancer. Am J Otolaryngol 26(5):308–313PubMedCrossRef
Zurück zum Zitat Kawano T et al (2005b) Soluble CD44 standard, CD44 variant 5 and CD44 variant 6 and their relation to staging in head and neck cancer. Acta Otolaryngol 125(4):392–397PubMedCrossRef Kawano T et al (2005b) Soluble CD44 standard, CD44 variant 5 and CD44 variant 6 and their relation to staging in head and neck cancer. Acta Otolaryngol 125(4):392–397PubMedCrossRef
Zurück zum Zitat Lackner C et al (1998) Soluble CD44 v5 and v6 in serum of patients with breast cancer. Correlation with expression of CD44 v5 and v6 variants in primary tumors and location of distant metastasis. Breast Cancer Res Treat 47(1):29–40PubMedCrossRef Lackner C et al (1998) Soluble CD44 v5 and v6 in serum of patients with breast cancer. Correlation with expression of CD44 v5 and v6 variants in primary tumors and location of distant metastasis. Breast Cancer Res Treat 47(1):29–40PubMedCrossRef
Zurück zum Zitat Lockhart MS et al (1999) Evaluation of soluble CD44 in patients with breast and colorectal carcinomas and non-Hodgkin’s lymphoma. Oncol Rep 6(5):1129–1133PubMed Lockhart MS et al (1999) Evaluation of soluble CD44 in patients with breast and colorectal carcinomas and non-Hodgkin’s lymphoma. Oncol Rep 6(5):1129–1133PubMed
Zurück zum Zitat Martin S et al (1997) Soluble CD44 splice variants in metastasizing human breast cancer. Int J Cancer 74(4):443–445PubMedCrossRef Martin S et al (1997) Soluble CD44 splice variants in metastasizing human breast cancer. Int J Cancer 74(4):443–445PubMedCrossRef
Zurück zum Zitat Molica S et al (2001) Elevated serum levels of soluble CD44 can identify a subgroup of patients with early B-cell chronic lymphocytic leukemia who are at high risk of disease progression. Cancer 92(4):713–719PubMedCrossRef Molica S et al (2001) Elevated serum levels of soluble CD44 can identify a subgroup of patients with early B-cell chronic lymphocytic leukemia who are at high risk of disease progression. Cancer 92(4):713–719PubMedCrossRef
Zurück zum Zitat Niitsu N, Iijima K (2002) High serum soluble CD44 is correlated with a poor outcome of aggressive non-Hodgkin’s lymphoma. Leuk Res 26(3):241–248PubMedCrossRef Niitsu N, Iijima K (2002) High serum soluble CD44 is correlated with a poor outcome of aggressive non-Hodgkin’s lymphoma. Leuk Res 26(3):241–248PubMedCrossRef
Zurück zum Zitat Ponta H, Sherman L, Herrlich PA (2003) CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 4(1):33–45PubMedCrossRef Ponta H, Sherman L, Herrlich PA (2003) CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 4(1):33–45PubMedCrossRef
Zurück zum Zitat Remmele W, Schicketanz KH (1993) Immunohistochemical determination of estrogen and progesterone receptor content in human breast cancer. Computer-assisted image analysis (QIC score) vs. subjective grading (IRS). Pathol Res Pract 189(8):862–866PubMed Remmele W, Schicketanz KH (1993) Immunohistochemical determination of estrogen and progesterone receptor content in human breast cancer. Computer-assisted image analysis (QIC score) vs. subjective grading (IRS). Pathol Res Pract 189(8):862–866PubMed
Zurück zum Zitat Sanchez Lockhart M et al (2001) Splice variant expression of CD44 in patients with breast and ovarian cancer. Oncol Rep 8(1):145–151PubMed Sanchez Lockhart M et al (2001) Splice variant expression of CD44 in patients with breast and ovarian cancer. Oncol Rep 8(1):145–151PubMed
Zurück zum Zitat Sheen-Chen SM et al (1999) Evaluation of the prognostic value of serum soluble CD 44 in patients with breast cancer. Cancer Invest 17(8):581–585PubMedCrossRef Sheen-Chen SM et al (1999) Evaluation of the prognostic value of serum soluble CD 44 in patients with breast cancer. Cancer Invest 17(8):581–585PubMedCrossRef
Zurück zum Zitat Stickeler E et al (2001) The RNA binding protein YB-1 binds A/C-rich exon enhancers and stimulates splicing of the CD44 alternative exon v4. Embo J 20(14):3821–3830PubMedCrossRef Stickeler E et al (2001) The RNA binding protein YB-1 binds A/C-rich exon enhancers and stimulates splicing of the CD44 alternative exon v4. Embo J 20(14):3821–3830PubMedCrossRef
Zurück zum Zitat Tempfer C et al (1996) Prognostic value of immunohistochemically detected CD44 isoforms CD44v5, CD44v6 and CD44v7–8 in human breast cancer. Eur J Cancer 32A(11):2023–2025PubMedCrossRef Tempfer C et al (1996) Prognostic value of immunohistochemically detected CD44 isoforms CD44v5, CD44v6 and CD44v7–8 in human breast cancer. Eur J Cancer 32A(11):2023–2025PubMedCrossRef
Metadaten
Titel
Increased soluble CD44 concentrations are associated with larger tumor size and lymph node metastasis in breast cancer patients
verfasst von
Sebastian Mayer
Axel zur Hausen
Dirk Otto Watermann
Stefan Stamm
Markus Jäger
Gerald Gitsch
Elmar Stickeler
Publikationsdatum
01.11.2008
Verlag
Springer-Verlag
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 11/2008
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-008-0397-z

Weitere Artikel der Ausgabe 11/2008

Journal of Cancer Research and Clinical Oncology 11/2008 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.